682 related articles for article (PubMed ID: 23669200)
1. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
[TBL] [Abstract][Full Text] [Related]
2. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M
J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802
[TBL] [Abstract][Full Text] [Related]
3. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
5. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
[TBL] [Abstract][Full Text] [Related]
7. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test.
von Laffert M; Penzel R; Schirmacher P; Warth A; Lenze D; Hummel M; Dietel M
J Thorac Oncol; 2014 Oct; 9(10):1464-9. PubMed ID: 25170635
[TBL] [Abstract][Full Text] [Related]
8. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
9. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR
J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337
[TBL] [Abstract][Full Text] [Related]
10. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches.
Demidova I; Grinevich V; Avdalian A; Imyanitov E; Gikalo M; Savelov N; Novikova I; Samuilenkova O; Tiurin V; Ulianova E; Tsimafeyeu I; Tjulandin S
Lung Cancer; 2017 Jan; 103():17-23. PubMed ID: 28024691
[TBL] [Abstract][Full Text] [Related]
11. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
[TBL] [Abstract][Full Text] [Related]
12. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
13. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
14. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
[TBL] [Abstract][Full Text] [Related]
15. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
17. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
[TBL] [Abstract][Full Text] [Related]
19. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.
Sullivan HC; Fisher KE; Hoffa AL; Wang J; Saxe D; Siddiqui MT; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):239-44. PubMed ID: 25265433
[TBL] [Abstract][Full Text] [Related]
20. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
